Backs FY26 adjusted EBITDA view $455M-$475M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Confident Leadership and Attractive Valuation Drive Buy Rating on Collegium (COLL)
- Collegium: Strategic AZSTARYS Acquisition Underpins ADHD Franchise Expansion and Supports Buy Rating
- Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise
- Collegium Pharmaceutical to acquire AZSTARYS for $650M in cash